B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women

Journal of the American College of Cardiology

Volumn 64, Issue 17, 2014, Pages 1789-1797

  Everett, Brendan M ^a   Berger, Jeffrey S ^b   Manson, Joann E ^a   Ridker, Paul M ^a   Cook, Nancy R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; multiethnic; prevention; risk prediction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; REYNOLDS RISK SCORE; RISK ASSESSMENT; RISK FACTOR; ALGORITHM; BLOOD; CLINICAL TRIAL; ETHNIC GROUP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; ALGORITHMS; CARDIOVASCULAR DISEASES; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TREATMENT OUTCOME; UNITED STATES;

EID: 84908215407     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.04.089     Document Type: Article

References (41)

1. A.S. Maisel, P. Krishnaswamy, and R.M. Nowak Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
2. J.L. Januzzi Jr.; C.A. Camargo, and S. Anwaruddin The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study Am J Cardiol 95 2005 948 954
3. K. Thygesen, J. Mair, and C. Mueller Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care Eur Heart J 33 2012 2001 2006
4. E. Di Angelantonio, R. Chowdhury, and N. Sarwar B-type natriuretic peptides and cardiovascular risk: systematic review and meta-Analysis of 40 prospective studies Circulation 120 2009 2177 2187
5. M.H. Olsen, T.W. Hansen, and M.K. Christensen N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population Eur Heart J 28 2007 1374 1381
6. B. Zethelius, L. Berglund, and J. Sundström Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 2008 2107 2116
7. O. Melander, C. Newton-Cheh, and P. Almgren Novel and conventional biomarkers for prediction of incident cardiovascular events in the community JAMA 302 2009 49 57
8. S. Blankenberg, T. Zeller, and O. Saarela Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project Circulation 121 2010 2388 2397
9. M.M. Redfield, R.J. Rodeheffer, S.J. Jacobsen, D.W. Mahoney, K.R. Bailey, and J.C. Burnett Jr. Plasma brain natriuretic peptide concentration: impact of age and gender J Am Coll Cardiol 40 2002 976 982
10. T.J. Wang, M.G. Larson, and D. Levy Impact of age and sex on plasma natriuretic peptide levels in healthy adults Am J Cardiol 90 2002 254 258
11. T.J. Wang, M.G. Larson, and D. Levy Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
12. C. Kistorp, I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 293 2005 1609 1616
13. T. Takahashi, M. Nakamura, and T. Onoda Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study Atherosclerosis 207 2009 298 303
14. National Heart, Lung, and Blood Institute. Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/06-ip-chtbk.pdf. Accessed August 14, 2013.
15. T.J. Wang, M.G. Larson, and D. Levy Impact of obesity on plasma natriuretic peptide levels Circulation 109 2004 594 600
16. E.R. Fox, S.K. Musani, and A. Bidulescu Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study Circulation 124 2011 1021 1027
17. N.K. Gupta, J.A. de Lemos, C.R. Ayers, S.M. Abdullah, D.K. McGuire, and A. Khera The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study J Am Coll Cardiol 60 2012 1148 1155
18. S.R. Das, M.H. Drazner, and D.L. Dries Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study Circulation 112 2005 2163 2168
19. D.G. Krauser, A.A. Chen, R. Tung, S. Anwaruddin, A.L. Baggish, and J.L. Januzzi Jr. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy J Card Fail 12 2006 452 457
20. J.A. Laukkanen, S. Kurl, and M. Ala-Kopsala Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-Aged men Eur Heart J 27 2006 1230 1237
21. R.B. D'Agostino Sr.; R.S. Vasan, and M.J. Pencina General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
22. P.M. Ridker, J.E. Buring, N. Rifai, and N.R. Cook Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
23. J.D. Curb, A. McTiernan, and S.R. Heckbert Outcomes ascertainment and adjudication methods in the Women's Health Initiative Ann Epidemiol 13 2003 S122 S128
24. W.E. Barlow Robust variance estimation for the case-cohort design Biometrics 50 1994 1064 1072
25. T.M. Therneau, and H. Li Computing the Cox model for case cohort designs Lifetime Data Anal 5 1999 99 112
26. B. Langholz, and J. Jiao Computational methods for case-cohort studies Comp Stats Data Analysis 51 2007 3737 3748
27. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
28. D.C. Goff Jr.; D.M. Lloyd-Jones, and G. Bennett 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
29. M.J. Pencina, R.B. D'Agostino Sr.; R.B. D'Agostino Jr.; and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
30. L.E. Chambless, C.P. Cummiskey, and G. Cui Several methods to assess improvement in risk prediction models: extension to survival analysis Stat Med 30 2011 22 38
31. M.J. Pencina, R.B. D'Agostino Sr.; and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
32. J.D. Berry, A. Dyer, and X. Cai Lifetime risks of cardiovascular disease N Engl J Med 366 2012 321 329
33. A.R. Folsom, V. Nambi, and E.J. Bell Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities study Stroke 44 2013 961 967
34. S. Sadanandan, C.P. Cannon, and K. Chekuri Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction J Am Coll Cardiol 44 2004 564 568
35. C. Kragelund, B. Gronning, L. Kober, P. Hildebrandt, and R. Steffensen N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease N Engl J Med 352 2005 666 675
36. T.J. Wang, K.C. Wollert, and M.G. Larson Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study Circulation 126 2012 1596 1604
37. N.P. Paynter, B.M. Everett, and N.R. Cook Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem 60 2014 88 97
38. J.T. Saunders, V. Nambi, and J.A. de Lemos Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities study Circulation 123 2011 1367 1376
39. J. Yeboah, R.L. McClelland, and T.S. Polonsky Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals JAMA 308 2012 788 795
40. N.J. Stone, J. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2014 2889 2934
41. M. Huelsmann, S. Neuhold, and M. Resl PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial J Am Coll Cardiol 62 2013 1365 1372